Aoxing Pharmaceutical Co. Inc. (AOXG)

Overview

Aoxing Pharmaceutical Company, Inc., stationed in Shijiazhuang, China, operates as a specialty pharmaceutical entity committed to the research and development, production, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals primarily within the People's Republic of China. Initially known as China Aoxing Pharmaceutical Company, Inc., the corporation underwent a name change to Aoxing Pharmaceutical Company, Inc. in March 2010. It has carved a niche in offering advanced pharmaceutical solutions, particularly focusing on addressing oral and dental pain, chronic pain management, and addiction treatments through its analytical and manufacturing capabilities.

Products and Services

Below is a detailed outline of Aoxing Pharmaceutical Company, Inc.'s primary products and those under development:

• Zhongtong'an Capsules: An herbal extraction offered in capsule form, specifically designed for the indication of oral and dental pain relief. This product embodies the company’s expertise in combining traditional Chinese medicinal knowledge with modern pharmaceutical practices.
• Yiqi Qiangshen Granule: This Over-The-Counter (OTC) herbal extract serves as a tonic designed for qi tonification, body empowerment, blood circulation enhancement, and meridian obstruction removal. It represents the company's commitment to holistic and traditional approaches to health and well-being.
• Tilidine Hydrochloride: A synthetic narcotic analgesic available in tablet form for oral administration, recommended in dosages of 50mg or 100mg. This medication is tailored for the relief of acute, moderate to severe pain, as well as for managing chronic cancer-related pain, showcasing the company’s efforts in addressing severe pain management.

In addition to the above products, Aoxing Pharmaceutical is invested in the development of new pharmaceutical solutions targeted at acute and chronic pain, as well as addiction treatment:

• Oxycodone and Acetaminophen Tablets and Capsules: Currently having completed clinical trials, these are designed for treating both acute and chronic pain, indicating a significant stride in the company's pain management portfolio.
• Buprenorphine/Naloxone Sublingual Tablets: Having completed Phase II clinical trials, this combination tablet is aimed at treating opioid dependence, reflecting the company’s dedication to addressing the global opioid crisis through pharmaceutical means.
• Tilidine/Naloxone Compound Capsules: Presently in Phase II clinical trials, this compound is developed for treating both acute and chronic pain, underscoring Aoxing’s ongoing efforts to expand its pain management solutions.